Physician profile
Yael Simons
NPI 1811342215
$1,166.97
in general payments reported to CMS, 2019-2025
12 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $392 · 2023: $296 · 2024: $176 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610 · Education: $24.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.56 |
| Education | $24.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $581.19 | 2022-2025 | Enhertu |
| Seagen INC. | $141.35 | 2021 | |
| Genzyme Corporation | $124.95 | 2022 | |
| Merck Sharp & Dohme LLC | $67.72 | 2022-2023 | Keytruda, Lynparza |
| Puma Biotechnology, INC. | $52.58 | 2023 | |
| Lilly USA, LLC | $47.91 | 2022-2023 | |
| Pfizer INC. | $40.66 | 2024-2025 | |
| Pacira Pharmaceuticals Incorporated | $37.48 | 2022 | |
| Gilead Sciences, INC. | $24.95 | 2023 | Trodelvy |
| Janssen Biotech, INC. | $17.00 | 2024 | Talvey, Tecvayli |
| Stemline Therapeutics INC. | $16.94 | 2025 | Orserdu |
| Organon LLC | $14.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yael Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.